Pediatrix Medical Group (MD) Projected to Post Earnings on Tuesday

Key Points

• Pediatrix Medical Group is set to release its Q2 2025 earnings on August 5th, expecting to report earnings of $0.42 per share and revenues of $464.37 million.
• The company saw a year-over-year revenue decline of 7.4% in its previous quarter, reporting a revenue of $458.36 million and EPS of $0.33.
• Analysts have mixed opinions on the stock, with a current consensus rating of "Hold" and an average target price of $16.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.42 per share and revenue of $464.37 million for the quarter.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.08. The company had revenue of $458.36 million for the quarter, compared to analysts' expectations of $451.44 million. Pediatrix Medical Group had a positive return on equity of 17.43% and a negative net margin of 4.17%. The firm's quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS. On average, analysts expect Pediatrix Medical Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $12.66 on Tuesday. Pediatrix Medical Group has a 12 month low of $7.47 and a 12 month high of $17.67. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.81 and a quick ratio of 1.81. The business's 50 day simple moving average is $13.60 and its 200-day simple moving average is $13.87. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -12.53 and a beta of 1.25.

Hedge Funds Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in Pediatrix Medical Group by 23.8% in the 1st quarter. Royal Bank of Canada now owns 22,097 shares of the company's stock valued at $320,000 after buying an additional 4,247 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Pediatrix Medical Group by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company's stock worth $743,000 after purchasing an additional 2,251 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Pediatrix Medical Group by 4.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company's stock worth $3,891,000 after purchasing an additional 12,171 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Macquarie upped their target price on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Truist Financial dropped their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, UBS Group dropped their price objective on Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating for the company in a report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of "Hold" and an average target price of $16.67.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.